Life Stem Genetics, Inc. (OTCBB: LIFS), an emerging innovator in the
advancement of Adult Stem Cell therapy, today announced that it has
added Dr. Shirin Rostamkalaee, an expert on wound healing, bone
grafting, and reconstructive surgery (broad areas with immense
applications for Adult Stem Cell (“ASC”) therapies) to its newly
expanded Executive Advisory Board. The addition of Dr. Rostamkalaee
follows the recent appointments of Matthew Sullivan, COO of global
health products company Asana International, and Shahab Bakhtyar, an
independent medical business consultant with extensive global
experience, to the company’s Executive Advisory Board.
Established earlier this year, the Executive Advisory Board has become a
cornerstone of Life Stem’s global stem-cell growth model. The company
has been actively retaining medical experts and business leaders who can
successfully guide the company’s expansion into key growth centers
throughout Europe, Asia, North America and the Middle East.
Dr. Rostamkalaee received her medical degree from the University of
Medical Sciences and Health Services. In addition to her vast experience
in patient care overseas and in Canada, Dr. Rostamkalaee completed her
medical thesis on usage of bone grafting in plastic and reconstructive
surgeries, an emergent area in the field of Adult Stem Cell therapies.
“Dr. Rostamkalaee is a world expert in the field of reconstructive
surgical methodologies, an area of medical science that is just
beginning to uncover the immense potential of Adult Stem Cell
therapies,” states Gloria Simov, President and CEO of Life Stem
Genetics. “We look forward to working with Dr. Rostamkalaee to explore
new methods of Adult Stem Cell treatment and are very fortunate to have
her guidance as we expand our base of ASC clinics in the United States
and internationally.”
About Life Stem Genetics
Life Stem Genetics (“LSG”) is a progressive healthcare company focused
on Adult Stem Cell (ASC) healing therapies. For decades, stem cells have
been utilized in the successful treatment of a variety of ailments.
Today, advanced ASC therapies are being offered to patients as an
efficient and painless alternative treatment for a wide range of
ailments including, but not limited to, orthopedic injuries,
neurological disorders such as Parkinson’s and Alzheimer’s, cancer,
arthritis, diabetes, multiple sclerosis, as well as age management.
Adult Stem Cell therapies and LSG’s proprietary techniques are
experiencing some of the best results in the industry in helping to
repair or reprogram damaged or diseased tissues and organs. Life Stem’s
ASC specialist has performed thousands of stem cell treatments including
some of the top names in PGA golf, NFL football, NBA basketball, and
Major League Baseball. LSG will offer its proprietary treatments through
a series of affiliate doctors and medical clinics with 60 affiliated
clinics thus far. LSG’s mission is to develop a comprehensive approach
to the treatment and maintenance of diseases while breaking free from
the medical insurance maze by tapping into an affordable private-pay
sector.
Contrarian Press, an established publisher, has been engaged by Life
Stem Genetics to assist with identification of potential market
participants who may be interested in learning more about the company
and its securities. Updated disclaimer and disclosure information is
available at the publisher's website and at the following link: http://www.contrarianwealthcoalition.com/guide/LIFS.pdf
For a copy of LIFS logo is available at: http://www.lifestemgenetics.com/wp-content/themes/LifeStemGenetics/images/life-stem-genetics-logo.png
This press release contains "forward-looking statements" within the
meaning of the "safe-harbor" provisions of the Private Securities
Litigation Reform Act of 1995 that are not historical facts. These
statements can be identified by the use of forward-looking terminology
such as "believe," "expect," "may”, “could”, “estimates”, "will,"
"should," "project," "plan," "seek," "intend," or "anticipate" or the
negative thereof or comparable terminology, and include discussions of
strategy, and statements about industry trends and the Company's future
performance, operations, and products. Such statements involve known and
unknown risks, uncertainties and other factors that could cause the
Company's actual results to differ materially from the results expressed
or implied by such statements. Such risks and uncertainties include,
without limitation, market acceptance of the Company's stem cell therapy
treatment program; the Company's compliance with applicable statutes and
regulations: the Company's reliance on third-party contractors to
provide suitable treatment facilities; the Company's ability to expand
its network of participating clinics and doctors; the Company's ability
to develop an effective marketing strategy; the Company's ability to
control and reduce advertising and marketing costs; the Company's
ability to develop and increase awareness of its brand; the Company's
ability to protect its trademarks; and the success of the Company's
marketing focus to patients, doctors and clinics. For a discussion of
these and other risks and uncertainties see "Risk Factors" and
“Description of Business” in the Company's public filings with the SEC.
Although the Company believes that the expectations reflected in such
forward-looking statements are reasonable, there can be no assurance
that such expectations will prove to be correct. The Company has no
obligation to update the forward-looking information contained in this
press release.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20131104005584r1&sid=ntxv4&distro=nx)
Copyright Business Wire 2013